Innovation
8 patent families (1 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace accelerating. Cited 308 times.
| Year | Filings |
|---|---|
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Investor mix
15 investors on record; lead investors include Cambrian BioPharma, Apeiron Investment Group, Catalio Capital Management, MedImmune; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 6 | 40% |
| Private equity | 1 | 7% |
| Accelerator & incubator | 1 | 7% |
| Other / undisclosed | 7 | 47% |